This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Patient Safety/ Medical Error  • Facial Plastic Surgery  • Cosmetic Surgery/ Procedures  • Infectious Diseases  • Alert me on articles by topic

Michael G. Brandt, MD; Maha Al Gilani, MD; Janet Balderston, MD; Ross Davidson, MD; Corey C. Moore, MD; Mark Taylor, MD

Arch Facial Plast Surg. 2009;11(4):271-273.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Since 1996, Restylane (Q-Medical, Uppsala, Sweden; distributed by Medicis Aesthetics Canada, Toronto, Ontario), a nonanimal stabilized hyaluronic acid (NASHA), has been used as a soft-tissue filler in Europe and Canada and, more recently, the United States. The longstanding safety, efficacy, and low immunogenicity profile of Restylane and the other NASHA fillers have made them the preferred choice for facial soft-tissue augmentation.^1-5 Restylane is provided in prefilled 0.5-mL and 1.0-mL single-dose syringes. Although the manufacturer does not recommend its use as a multidose syringe, based largely on the cost of the product, it has been our practice to save any unused portion of the prefilled syringe for future dosing in the same patient. This practice has been well received by patients because they occasionally require a repeated injection after 2 . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION